Curated News
By: NewsRamp Editorial Staff
August 11, 2026
Helus Pharma CEO to Speak at Canaccord Conference
TLDR
- Helus Pharma CEO's fireside chat at Canaccord conference offers investors key insights into its Phase 3 depression drug, HLP003.
- Helus Pharma's HLP003, a novel serotonergic agonist, is in Phase 3 for major depressive disorder, with FDA Breakthrough Therapy Designation.
- Helus Pharma's novel drugs aim to provide durable improvements in mental health, addressing unmet needs for depression and anxiety patients.
- Helus Pharma, formerly Cybin, is developing synthetic molecules that activate serotonin pathways to promote neuroplasticity in the brain.
Impact - Why it Matters
This news matters because it highlights Helus Pharma's ongoing efforts to develop innovative treatments for depression and anxiety, which affect millions worldwide. The company's participation in a major growth conference signals its commitment to transparency and investor engagement, providing stakeholders with insights into its clinical progress and strategic direction. As mental health challenges continue to rise, the advancement of novel therapies like HLP003 and HLP004 could offer new hope for patients and potentially reshape the treatment landscape, making this a significant development for both the company and the broader healthcare sector.
Summary
Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), announced that CEO Michael Halstead will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference, scheduled for August 11-12, 2026. The chat will be webcast live on August 12 at noon EDT, with a replay available on the company's investor relations website. This event underscores Helus Pharma's commitment to engaging with the investment community as it advances its pipeline of innovative treatments for mental health conditions.
Helus Pharma, the commercial operating name of Cybin Inc., is at the forefront of developing NSAs—synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The company's lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004 is in Phase 2 for generalized anxiety disorder. With a mission to address the large unmet need in mental health, Helus Pharma aims to improve treatment outcomes through durable and effective therapies.
For more details, the full press release is available at https://ibn.fm/eUotH. To learn more about Helus Pharma, visit www.helus.com or follow the company on social media platforms. This news was disseminated by MissionIR, a specialized communications platform, as part of its services to enhance visibility for companies within the investment community.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Helus Pharma CEO to Speak at Canaccord Conference
